期刊
ONCOTARGETS AND THERAPY
卷 15, 期 -, 页码 407-410出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S315385
关键词
adverse events; anemia; EGFR; neutropenia; non-small cell lung cancer; osimertinib; pancytopenia; thrombocytopenia
资金
- Consorzio Interuniversitario Nazionale per la Bio Oncologia
This case report describes a patient with EGFR-mutated NSCLC who developed pancytopenia during treatment with osimertinib, but showed excellent activity after dose reduction. This suggests that osimertinib can be safely resumed at a reduced dose even after adverse events.
Background: Osimertinib is an irreversible tyrosine kinase inhibitor approved for the treatment of metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). In clinical trials, osimertinib has exhibited excellent activity and less toxicity compared to gefitinib, erlotinib and standard chemotherapy. Case Presentation: Herein, we describe the case of a 69-year-old man who received first-line osimertinib for metastatic EGFRmutated NSCLC. Suspected osimertinib-induced pancytopenia together with a partial treatment response was assessed after 10 days of therapy. Osimertinib was resumed at 40 mg daily a month later while the patient exhibited durable stable disease. No other adverse events occurred. Conclusion: In the current case, first-line treatment with osimertinib at 80 mg daily in a patient with EGFR-mutated NSCLC resulted in severe pancytopenia and a rapid treatment response. Dose reduction to 40 mg daily resulted in excellent activity without any further adverse events. Osimertinib could be safely resumed at a reduced dose even after pancytopenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据